Sage Therapeutics (SAGE) News Today $9.12 +0.05 (+0.55%) Closing price 06/17/2025 04:00 PM EasternExtended Trading$9.11 -0.01 (-0.11%) As of 06/17/2025 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Why is Sage Therapeutics Up Today?Sage Therapeutics (NASDAQ: SAGE) shares have jumped on news that Supernus Pharmaceuticals will acquire the company for up to $795 million, securing rights to Sage’s depression drug Zurzuvae. The takeover offer of $8.50 in cash per share plus a contingent value right worth up to $3.50 has driven trading interest, while analysts’ price‐target revisions and multiple shareholder‐led investigations add nuance to the outlook. Supernus deal: $8.50 cash plus CVR up to $3.50, implying potential total value near $12 per share HC Wainwright reaffirmed a neutral rating with a $12.00 price target (31.6% upside) Truist Financial raised its price target from $8.00 to $9.00 with a “hold” rating Canaccord Genuity lifted its target from $8.00 to $8.50 with a “hold” rating Piper Sandler kept a neutral rating but cut its target to $8.50 from $9.00 Needham & Company reiterated its “hold” rating on the stock Zacks notes a 35.4% share jump on heavy volume, but warns that recent earnings‐estimate revisions are not signaling further strength Trading was briefly halted early Tuesday amid pending news Multiple law firms (Bronstein, Rowley, Halper Sadeh, The Ademi Firm) are investigating whether the sale price is fair, potentially leading to litigation and deal delays Posted 6h agoAI Generated. May Contain Errors. SAGE Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Sage Therapeutics (NASDAQ:SAGE) Earns Neutral Rating from Piper SandlerPiper Sandler restated a "neutral" rating and set a $8.50 target price (down previously from $9.00) on shares of Sage Therapeutics in a research note on Tuesday.June 17 at 11:36 AM | marketbeat.comSage Therapeutics (NASDAQ:SAGE) Price Target Raised to $9.00Truist Financial boosted their price target on Sage Therapeutics from $8.00 to $9.00 and gave the stock a "hold" rating in a research report on Tuesday.June 17 at 10:56 AM | marketbeat.comHC Wainwright Reaffirms "Neutral" Rating for Sage Therapeutics (NASDAQ:SAGE)HC Wainwright reaffirmed a "neutral" rating and set a $12.00 target price on shares of Sage Therapeutics in a research note on Tuesday.June 17 at 10:37 AM | marketbeat.comSage Therapeutics (NASDAQ:SAGE) Given New $8.50 Price Target at Canaccord Genuity GroupCanaccord Genuity Group upped their price target on shares of Sage Therapeutics from $8.00 to $8.50 and gave the company a "hold" rating in a research note on Tuesday.June 17 at 8:34 AM | marketbeat.comSupernus makes depression drug play with $795m Sage buyoutJune 17 at 12:27 AM | msn.comSage Therapeutics Stock Soars 36% After Sale to Supernus Pharmaceuticals. What We Know.June 17 at 12:27 AM | msn.comALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Sage Therapeutics, Inc.June 16 at 5:31 PM | prnewswire.comSage Therapeutics (NASDAQ:SAGE) Shares Gap Up - Should You Buy?Sage Therapeutics (NASDAQ:SAGE) Shares Gap Up - Should You Buy?June 16 at 12:52 PM | marketbeat.comSAGE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Sage Therapeutics, Inc. Is Fair to ShareholdersJune 16 at 9:10 AM | businesswire.comNeedham & Company LLC Reiterates "Hold" Rating for Sage Therapeutics (NASDAQ:SAGE)Needham & Company LLC reissued a "hold" rating on shares of Sage Therapeutics in a report on Monday.June 16 at 8:55 AM | marketbeat.comShareholder Alert: The Ademi Firm Investigates Whether Sage Therapeutics, Inc. ...June 16 at 8:52 AM | gurufocus.comSage Therapeutics Stock Soars 35% After Sale to Supernus. What We Know.June 16 at 7:42 AM | barrons.comShareholder Alert: The Ademi Firm Investigates Whether Sage Therapeutics, Inc. Is Obtaining a Fair Price for Its Public ShareholdersJune 16 at 7:38 AM | businesswire.comSupernus Pharma to acquire Sage Therapeutics in up to $795 million dealJune 16 at 7:14 AM | reuters.comContrasting Sage Therapeutics (NASDAQ:SAGE) & Orgenesis (NASDAQ:ORGS)June 14, 2025 | americanbankingnews.comSage Therapeutics, Inc. (NASDAQ:SAGE) Given Consensus Rating of "Hold" by AnalystsSage Therapeutics, Inc. (NASDAQ:SAGE - Get Free Report) has been assigned an average recommendation of "Hold" from the seventeen research firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, fourteeJune 11, 2025 | marketbeat.comSquarepoint Ops LLC Has $126,000 Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)Squarepoint Ops LLC decreased its position in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 83.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,134 shares of theJune 10, 2025 | marketbeat.comWall Street Zen Downgrades Sage Therapeutics (NASDAQ:SAGE) to SellWall Street Zen cut Sage Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday.June 7, 2025 | marketbeat.comMajor Depressive Disorder Pipeline Appears Robust With 75+ Key Companies Actively Working in the Therapeutics Segment | DelveInsightJune 5, 2025 | theglobeandmail.comBank of America Corp DE Sells 355,277 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)Bank of America Corp DE lessened its holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 52.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 316,673 shares of the biopharmaceutical company's stock after sellingJune 4, 2025 | marketbeat.comAmeriprise Financial Inc. Trims Stake in Sage Therapeutics, Inc. (NASDAQ:SAGE)Ameriprise Financial Inc. trimmed its holdings in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 41.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 125,630 shares of the biopharmacJune 4, 2025 | marketbeat.comToronto Dominion Bank Makes New $742,000 Investment in Sage Therapeutics, Inc. (NASDAQ:SAGE)Toronto Dominion Bank bought a new stake in Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 136,723 shares of the biopharmaceutical company's stock,June 1, 2025 | marketbeat.comSage Therapeutics (NASDAQ:SAGE) Stock Rating Upgraded by Wall Street ZenWall Street Zen upgraded Sage Therapeutics from a "sell" rating to a "hold" rating in a report on Friday.June 1, 2025 | marketbeat.comVoloridge Investment Management LLC Cuts Stock Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)Voloridge Investment Management LLC lowered its stake in Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 72.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 87,981 shares of the biopMay 31, 2025 | marketbeat.comMan Group plc Takes Position in Sage Therapeutics, Inc. (NASDAQ:SAGE)Man Group plc acquired a new stake in Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 62,900 shares of the biopharmaceutical company's stock, valued at approximately $342,000. ManMay 28, 2025 | marketbeat.com136,723 Shares in Sage Therapeutics, Inc. (NASDAQ:SAGE) Purchased by Toronto Dominion BankToronto Dominion Bank acquired a new position in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 136,723 shares of the biopharmaceutical cMay 27, 2025 | marketbeat.comSage Therapeutics, Inc. (NASDAQ:SAGE) Shares Purchased by Millennium Management LLCMillennium Management LLC grew its stake in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 8.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,623,785 shares of theMay 27, 2025 | marketbeat.comLazard Asset Management LLC Buys New Stake in Sage Therapeutics, Inc. (NASDAQ:SAGE)Lazard Asset Management LLC bought a new stake in Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 222,726 shares of the biopharmaceutical company's stock, valued at approMay 22, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Buys 114,173 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)D. E. Shaw & Co. Inc. raised its stake in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 18.8% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 720,105 shares of the biopharmaceutical company's stock after puMay 21, 2025 | marketbeat.comNeuromodulation: rewiring healthcare?May 19, 2025 | msn.comSage Therapeutics, Inc. (NASDAQ:SAGE) Receives Consensus Rating of "Hold" from BrokeragesSage Therapeutics, Inc. (NASDAQ:SAGE - Get Free Report) has been given a consensus rating of "Hold" by the nineteen ratings firms that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, fifteen have assigned a holdMay 19, 2025 | marketbeat.comRTW Investments LP Lowers Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)RTW Investments LP lowered its holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 46.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,002,370 shares of the biopharmaceutical company's stock after selling 2,589,330 sharesMay 18, 2025 | marketbeat.comJane Street Group LLC Raises Position in Sage Therapeutics, Inc. (NASDAQ:SAGE)Jane Street Group LLC lifted its stake in Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 103.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 462,004 shares of the biopharmaceutical company's stock after buMay 18, 2025 | marketbeat.comCubist Systematic Strategies LLC Acquires Shares of 152,726 Sage Therapeutics, Inc. (NASDAQ:SAGE)Cubist Systematic Strategies LLC acquired a new stake in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 152,726 shares of the bioMay 17, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Reduces Stake in Sage Therapeutics, Inc. (NASDAQ:SAGE)Jacobs Levy Equity Management Inc. trimmed its stake in Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 10.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,123,308 shares of the biopharmaMay 16, 2025 | marketbeat.comAlgert Global LLC Sells 104,738 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)Algert Global LLC lowered its holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 73.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 38,296 shares of the biopharmaceutical company's stock after selling 10May 16, 2025 | marketbeat.comJ.P. Morgan Keeps Their Hold Rating on SAGE Therapeutics (SAGE)May 10, 2025 | theglobeandmail.comMajor Depressive Disorder Pipeline Report 2025: Comprehensive Insights of 75+ Companies and Drugs Under Clinical AssessmentMay 8, 2025 | finance.yahoo.comTrinity Life Sciences Announces Winners of TGaS Advisors Best of Benchmark Awards for Operational Excellence in Pharma IndustryMay 6, 2025 | finance.yahoo.comHC Wainwright Issues Optimistic Estimate for SAGE EarningsSage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - HC Wainwright raised their Q2 2025 earnings estimates for Sage Therapeutics in a research note issued on Wednesday, April 30th. HC Wainwright analyst D. Tsao now anticipates that the biopharmaceutical company will post earnings per share of ($May 4, 2025 | marketbeat.comWedbush Equities Analysts Raise Earnings Estimates for SAGESage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - Stock analysts at Wedbush lifted their Q2 2025 earnings per share estimates for shares of Sage Therapeutics in a research note issued on Tuesday, April 29th. Wedbush analyst L. Chico now forecasts that the biopharmaceutical company will post eMay 4, 2025 | marketbeat.comSusquehanna Fundamental Investments LLC Invests $1.17 Million in Sage Therapeutics, Inc. (NASDAQ:SAGE)Susquehanna Fundamental Investments LLC acquired a new stake in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 215,8May 4, 2025 | marketbeat.comBrokers Issue Forecasts for SAGE Q1 EarningsSage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Sage Therapeutics in a note issued to investors on Wednesday, April 30th. HC Wainwright analyst D. Tsao expects that the biopharmaceutiMay 3, 2025 | marketbeat.comCaligan Partners LP Makes New Investment in Sage Therapeutics, Inc. (NASDAQ:SAGE)Caligan Partners LP acquired a new stake in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 3,052,538 shares of the biopharmaMay 3, 2025 | marketbeat.comPDT Partners LLC Buys 63,804 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)PDT Partners LLC lifted its stake in Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 37.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 235,097 shares of the biopharmaceutical company's sMay 3, 2025 | marketbeat.comSage Therapeutics (NASDAQ:SAGE) Releases Earnings Results, Misses Estimates By $0.01 EPSSage Therapeutics (NASDAQ:SAGE - Get Free Report) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($1.00) by ($0.01). Sage Therapeutics had a negative net margin of 971.50% and a negative return on equity of 68.18%.May 1, 2025 | marketbeat.comQ1 2025 SAGE Therapeutics Inc Earnings CallMay 1, 2025 | finance.yahoo.comSage Therapeutics Inc (SAGE) Q1 2025 Earnings Call Highlights: Strong Demand for ZURZUVAE and ...May 1, 2025 | finance.yahoo.comVirtus ETF Advisers LLC Buys 33,029 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)Virtus ETF Advisers LLC grew its position in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 115.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 61,668 shares of the biopharmaceuticalApril 30, 2025 | marketbeat.comSage Therapeutics, Inc. (SAGE) Q1 2025 Earnings Call TranscriptApril 29, 2025 | seekingalpha.com Get Sage Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter. Email Address SAGE Media Mentions By Week SAGE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SAGE News Sentiment▼0.280.90▲Average Medical News Sentiment SAGE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SAGE Articles This Week▼229▲SAGE Articles Average Week Get Sage Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NewAmsterdam Pharma News Today Bausch Health Companies News Today Arrowhead Pharmaceuticals News Today Denali Therapeutics News Today Twist Bioscience News Today Vericel News Today Kiniksa Pharmaceuticals News Today Agios Pharmaceuticals News Today Sarepta Therapeutics News Today Recursion Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SAGE) was last updated on 6/18/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWhat 99% of investors are missing about Chinese AIChinese AI chatbot DeepSeek's release put the spotlight on AI and turned the tech world on its head. But 99...Weiss Ratings | SponsoredWill I be blacklisted?The President’s tour of the Middle East… the deal for Ukraine’s mineral rights… Elon’s strange time in Washing...Porter & Company | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sage Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sage Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SAGE Stock Free SAGE Stock Alerts